G1GLP1 Note Applies to All countries

HomeNew drugsZepbound

New drugsAll countries · Checked

Tirzepatide FDA Approval: Dates for Mounjaro and Zepbound and What Is Next

The FDA approved tirzepatide as Mounjaro for type 2 diabetes on May 13, 2022, and as Zepbound for weight loss on November 8, 2023. Sleep apnea was added to Zepbound on December 20, 2024.

When did the FDA approve tirzepatide?

Twice, under two brand names. Mounjaro for diabetes came first, and Zepbound for weight loss followed about 18 months later.

Mounjaro, type 2 diabetesMay 13, 2022

Zepbound, weight lossNovember 8, 2023

Zepbound, sleep apnea addedDecember 20, 2024

Mounjaro, heart and stroke risk addedAugust 27, 2026

Based on FDA records and the current US prescribing information.

Once you know what is approved, the next question is the dose.

See the Zepbound dose chart from 2.5 mg to 15 mg

Want the cost? See Zepbound cost per dose in the US.

Approval datesZepboundMounjaroMounjaro for weight lossUK and EuropeWhat is nextFAQ

Tirzepatide FDA approval dates

Tirzepatide is one medicine with two US brand names, and each brand has its own approval history. Mounjaro is the diabetes brand. Zepbound is the weight and sleep apnea brand.

FDA approval dates

May 13, 2022Mounjaro for type 2 diabetes

November 8, 2023Zepbound for weight loss and weight maintenance

December 20, 2024Zepbound for sleep apnea in adults with obesity

December 2025Mounjaro for ages 10 and up with type 2 diabetes

August 27, 2026Mounjaro to lower the risk of heart attack and stroke

All of these dates are for the US. The UK and Europe have their own dates, covered below.

FDA approves Zepbound for weight loss

On November 8, 2023, the FDA approved Zepbound for chronic weight management. It is for adults, alongside a reduced-calorie diet and more physical activity.

You qualify with a BMI of 30 or higher, or a BMI of 27 or higher plus at least one weight-related condition, such as high blood pressure, type 2 diabetes or high cholesterol.

The name can confuse people, because the same medicine had already been on the US market for 18 months as Mounjaro.

On December 20, 2024, the FDA added a second use: moderate to severe obstructive sleep apnea in adults with obesity. The dose for sleep apnea is 10 mg or 15 mg once a week.

The Zepbound label carries a boxed warning about thyroid C-cell tumors. It is not for anyone with a personal or family history of medullary thyroid cancer, or with multiple endocrine neoplasia syndrome type 2.

Dosing starts at 2.5 mg once a week and tops out at 15 mg. The full schedule is in Zepbound dosing schedule.

FDA approves Mounjaro

Mounjaro was approved on May 13, 2022, as a new molecular entity. Its first use was to improve blood sugar control in adults with type 2 diabetes.

Two uses came later. One is type 2 diabetes in children and teenagers aged 10 and older, added in December 2025. The other, added on August 27, 2026, is lowering the risk of heart attack, stroke and cardiovascular death in adults with type 2 diabetes who are at high risk.

The maximum dose for the pediatric use is 10 mg. Adult doses are laid out in Mounjaro dosing.

Is Mounjaro FDA approved for weight loss?

No. In the US, only Zepbound is approved for weight loss. The Mounjaro label lists type 2 diabetes and cardiovascular risk reduction, and no weight indication.

The medicine and the dose range are the same. What differs is the approved use, and with it how insurers treat the prescription.

The UK and Europe work differently. There, one brand name, Mounjaro, is approved for both diabetes and weight loss.

Tirzepatide approval dates in the UK and Europe

The UK regulator, the MHRA, approved Mounjaro for weight loss and weight management on November 8, 2023, the same day the FDA approved Zepbound.

UK adults aged 18 and over qualify with a BMI of 30 or more, or a BMI from 27 to under 30 plus a weight-related problem such as prediabetes, high blood pressure, high cholesterol or heart problems.

In the European Union, the European Commission amended the Mounjaro marketing authorisation on December 11, 2023, to add a new therapeutic indication. The original diabetes authorisation dates from 2022.

Approval and NHS access are separate questions. The coverage rules are in Mounjaro on the NHS, and UK prices are in Mounjaro price UK.

Tirzepatide FDA: what is next

The nearest big date is a trial rather than an approval. SURMOUNT-MMO, a study of tirzepatide on illness and death in adults with obesity, has an estimated primary completion date of October 2027.

It has finished enrolling and is listed as active. The date is an estimate on ClinicalTrials.gov and can move.

Whether a generic tirzepatide exists is covered in tirzepatide generic name. Other medicines still in development are in new weight loss drugs and retatrutide FDA approval.

Tirzepatide FDA approval FAQ

When did the FDA approve tirzepatide?

On May 13, 2022, as Mounjaro for type 2 diabetes. The weight loss version, Zepbound, was approved on November 8, 2023.

Is Zepbound FDA approved?

Yes. It was approved for weight management on November 8, 2023, and for obstructive sleep apnea on December 20, 2024.

Are Mounjaro and Zepbound the same medicine?

Yes. Both contain tirzepatide. They differ in brand name and in the uses approved in the US.

Can I get Mounjaro for weight loss?

In the US, Zepbound is the weight loss brand. In the UK and Europe, Mounjaro itself is approved for weight management.

Did the FDA approve Mounjaro for heart protection?

Yes. On August 27, 2026, the FDA added a use to lower the risk of heart attack, stroke and cardiovascular death in adults with type 2 diabetes who are at high risk.

Keep reading

Zepbound dosing schedule

Mounjaro dosing chart

Zepbound cost in the US

Mounjaro on the NHS

Tirzepatide generic name

New weight loss drugs

Dates on this page come from FDA records, the prescribing information and UK and EU regulator documents. See how we check our pages.

Update log

: First published.

Sources

U.S. Food and Drug Administration, FDA approves new medication for chronic weight management (November 8, 2023).

U.S. Food and Drug Administration, Drugs@FDA approval history for Zepbound and its prescribing information.

U.S. Food and Drug Administration, Drugs@FDA approval history for Mounjaro, and Eli Lilly, Mounjaro prescribing information.

Medicines and Healthcare products Regulatory Agency, MHRA authorises Mounjaro for weight management (November 8, 2023).

European Commission, Implementing Decision C(2023)8876 on Mounjaro (December 11, 2023).

ClinicalTrials.gov, SURMOUNT-MMO (NCT05556512).

GLP1 Note is an independent information site. Whether to use tirzepatide, and under which brand, is decided with your prescriber.